Patel Featured on BPCIA Litigation to Watch
Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel was featured on the ongoing Biologics Price Competition and Innovation Act (BPCIA) Litigation he is watching.
“I am watching very closely the litigation involving biologics that are related to rheumatoid arthritis,” Sal said. “There are a number of them going on, and I think that what happens in those cases and how those companies are going to be able to penetrate the market is going to determine whether other companies — smaller companies that have developed biosimilars in places like India, where they have developed and launched them — whether they will get into the biosimilar game in the United States.”
Watch the full video here.
Contacts
- Related Industries
- Related Practices